112 related articles for article (PubMed ID: 31764016)
1. A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer.
Syed S; Basourakos SP; Ali FS; Garcia JL; Zurita-Saavedra A; Gong Z
Am J Clin Oncol; 2020 Feb; 43(2):87-93. PubMed ID: 31764016
[TBL] [Abstract][Full Text] [Related]
2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
3. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
4. Current trend of worsening prognosis of prostate small cell carcinoma: A population-based study.
Wang J; Liu X; Wang Y; Ren G
Cancer Med; 2019 Nov; 8(15):6799-6806. PubMed ID: 31518071
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
7. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases.
Martínez-Piñeiro L; Rios E; Martínez-Gomariz M; Pastor T; de Cabo M; Picazo ML; Palacios J; Perona R
Eur Urol; 2003 Apr; 43(4):342-50. PubMed ID: 12667714
[TBL] [Abstract][Full Text] [Related]
8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
9. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
10. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
11. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
[TBL] [Abstract][Full Text] [Related]
12. Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?
Cooke EW; Shrieve DC; Tward JD
Am J Clin Oncol; 2012 Aug; 35(4):364-8. PubMed ID: 21436673
[TBL] [Abstract][Full Text] [Related]
13. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
[TBL] [Abstract][Full Text] [Related]
14. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
15. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
16. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
[TBL] [Abstract][Full Text] [Related]
17. Risk of prostate carcinoma death in patients with lymph node metastasis.
Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
19. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]